# ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

> **NCT05071937** · PHASE2 · RECRUITING · sponsor: **Alexander B Olawaiye, MD** · enrollment: 33 (estimated)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** ZEN003694
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT05071937
- **Lead sponsor:** Alexander B Olawaiye, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-21
- **Primary completion:** 2031-12-31
- **Final completion:** 2033-03-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-06-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071937, "ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05071937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*